DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for hereditary elliptocytosis — screening already-approved drugs against its 6-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHereditary elliptocytosis maps to a 6-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hereditary elliptocytosis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
erythrocyte membrane protein band 4.1 (EPB41) — EPB41 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet unxdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3QIJ · 1.8 Å · ligand UNKNOWN ATOM OR ION (UNX). Experimental structure, not a prediction.
What the evidence adds up to
A 2018 study of a single patient with hereditary elliptocytosis used SDS-PAGE to look for erythrocyte membrane protein defects but found no difference between the patient and healthy controls. Sanger sequencing of the SPTA1 gene identified three mutations: a c.5077A>C (p.Lys1693Gln) missense mutation in exon 36, a c.5572C>G (p.Leu1858Val) missense mutation in exon 40, and a IVS45nt-12C>T mutation in intron 45. The father and grandmother were heterozygous for the first mutation; the mother was heterozygous for the other two. The authors concluded that the disease in this patient may result from the synergistic action of all three mutations.
A 1974 case report described a girl with both hereditary spherocytosis and hereditary elliptocytosis who had a moderately severe haemolytic anaemia. The authors suggested this could be due to a summation of the clinical effects of the genes involved, or to mutual enhancement of the genes from each condition. A 2022 case report noted that hereditary elliptocytosis is a group of red blood cell membrane disorders characterised by elliptical erythrocytes and shortened red blood cell survival, caused by protein abnormalities in the horizontal skeletal network of the cell membrane, specifically the spectrin dimer-dimer interaction or the spectrin-actin-protein 4.1 junction complex. A 2007 commentary on a study by Johnson and colleagues stated that proline substitutions in linkers between spectrin repeats provide a conformational basis for hereditary elliptocytosis by destabilising the linker.
No drug treatment is mentioned in any of these abstracts. What is missing is any clinical trial data, any tested intervention, any patient stratification beyond single-case genetics, and any funding for a repurposing study.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
PubMed · 2018 · 2 citations
[Analysis of SPTA1 gene mutations in a patient with hereditary elliptocytosis].
AbstractOBJECTIVE: To detect disease-causing mutations in a patient with hereditary elliptocytosis. METHODS: Sodium dodecyl sulfate polyacrylamide gel electropheresis (SDS-PAGE) was used to identify the type of erythrocyte membrane protein defect. Potential mutations of the exons and adjacent introns of relevant genes were analyzed by Sanger sequencing. RESULTS: SDS-PAGE has failed to detect any difference between the patient and healthy controls. However, Sanger sequencing has detected three mutations in the SPTA1 gene in the patient, which included c.5077A>C (p.Lys1693Gln) missense mutation in exon 36, c.5572C>G (p.Leu1858Val) missense mutation in exon 40, and a IVS45nt-12C>T in intron 45. The father and grandmother of the patient were both heterozygous for c.5077A>C mutation, while her mother was heterozygous for c.5572C>G and IVS45nt-12C>T mutations. CONCLUSION: The hereditary elliptocytosis in the patient may be attributed to the synergistic action of c.5077A>C, c.5572C>G and IVS45nt-12C>T mutations of the SPTA1 gene.
Combination of hereditary elliptocytosis and hereditary spherocytosis
AbstractA girl with the combination of hereditary spherocytosis and hereditary elliptocytosis is presented. She had a moderately severe haemolytic anaemia. This was the result either of a summation of the clinical effects of the involved genes or of the mutual enhancement of any of genes involved in the two conditions.
Archives of Hematology Case Reports and Reviews · 2022 · 0 citations · open access
Hereditary elliptocytosis discovered during work-up for infective endocarditis: About a case
AbstractHereditary elliptocytosis is a group of red blood cell membrane disorders that are characterized by elliptical-shaped erythrocytes and shortened red blood cell survival [1]. It is due to protein abnormalities involving the horizontal skeletal network of the red cell membrane, including the spectrin dimer-dimer interaction or the spectrin-actin-protein 4.1 junction complex [2].
Abstract[Comment on Johnson et al, page 3538][1]In this issue, Johnson and colleagues provide a conformational basis for hereditary elliptocytosis (HE) due to proline substitutions in linkers between spectrin repeats.
![Figure][2]
Molecular model showing destabilization of the linker (blue)
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
